D e s i g n Inception cohort followed for 12 months.
S e t t i n g
Catchment area of 100 000 people for 62 general practitioners in Iceland. M a i n r e s u l t s Sex was not a predictor of postherpetic neuralgia at any point during follow-up. Age was a predictor of pain severity and duration. The odds ratio for pain per 10 years of age difference was 1.87 (95% CI 1.56 to 2.23) after 1 month, 2.11 (CI 1.56 to 2.84) after 3 months, and 2.33 (CI 1.48 to 3.69) after 12 months. In patients < 60 years of age, the prevalence of postherpetic neuralgia was low, and no patients had more than mild pain after 3 months (5 patients [1.8%] after 3 mo; 2 patients [0.7%] after 12 mo). In patients ≥ 60 years of age, the frequency and severity of neuralgia increased. After 3 months, 23 patients (20%) had pain, and 2 patients (1.7%) had severe pain. After 12 months, 12 patients (9.4%) had pain, but none had severe pain. None of a random sample of 183 patients who were free of neuralgia at 12 months reported any recurrence of pain during long-term follow-up (3.2 to 7.0 y). Among 14 patients (all ages) who reported pain after 12 months, 12 considered the pain mild.
C o n c l u s i o n s
In patients with a first episode of herpes zoster, the course of disease was benign among those < 60 years of age. In older patients, the frequency of neuralgia increased, but pain severity was rarely more than mild. Patients free of pain had no pain recurrence. 
C o m m e n t a r y
The community-based, prospective study by Helgason and colleagues of 421 patients with a first episode of herpes zoster found that the point prevalence of postherpetic neuralgia after 1 month was only 19%, after 3 months was 7%, after 1 year was 3%, and after 3 years was about 1%. These results are consistent with previous community-based studies (1) but are lower than the 3-month point prevalence estimates of 33% to 43% observed among patients enrolled in trials of antiviral agents who were allocated to placebo (2) . The higher prevalence of postherpetic neuralgia in clinical trials is mainly caused by selection bias; severe cases of postherpetic neuralgia (e.g., older patients with severe pain and rash) are more likely to be referred to a hospital and enrolled in trials. In the study by Helgason and colleagues, the prevalence of postherpetic neuralgia at 3 months among patients > 60 years of age (20%) was similar to that observed among 181 patients of the same age in the placebo arm of a clinical trial (24%) (3) .
Although individual trials suggest that antiviral drugs (famciclovir and valaciclovir) reduce the prevalence of postherpetic neuralgia by as much as 50%, a recent meta-analysis suggests a more conservative treatment effect (2) .
If antiviral therapy reduces postherpetic neuralgia by 25% (which needs to be confirmed), then treating all 421 patients in Helgason and colleagues' study would have reduced postherpetic neuralgia at 1 month from 19% to 14.25% (absolute risk reduction [ARR] 4.75%, n = 20, number needed to treat [NNT] = 21); at 3 months, from 7% to 5.25% (ARR = 1.75%, n = 7, NNT = 57); and at 1 year, from 3% to 2.25% (ARR = 0.75%, n = 32, NNT = 133). Restricting antiviral therapy to the 115 patients > 60 years of age would reduce postherpetic neuralgia at 3 months from 20% to 15% (ARR = 5%, n = 6, NNT = 20), saving 6 patients from postherpetic neuralgia at 3 months compared with 7 patients if all patients were treated.
This study highlights that herpes zoster is benign for most patients and that treatment of all patients with antiviral therapy is unnecessary.
